Screener
Gilead Sciences GILD Trodelvy — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000882095-26-000031
| (in millions) | Three Months Ended June 30, 2026 / U.S. | Three Months Ended June 30, 2026 / Europe | Three Months Ended June 30, 2026 / Rest of World | Three Months Ended June 30, 2026 / Total | Three Months Ended June 30, 2025 / U.S. | Three Months Ended June 30, 2025 / Europe | Three Months Ended June 30, 2025 / Rest of World | Three Months Ended June 30, 2025 / Total |
|---|---|---|---|---|---|---|---|---|
| Tecartus | 29 | 34 | 8 | 70 | 41 | 41 | 9 | 92 |
| Yescarta | 132 | 139 | 75 | 346 | 162 | 154 | 77 | 393 |
| Total Cell Therapy | 161 | 173 | 83 | 417 | 203 | 196 | 86 | 485 |
| Trodelvy | 307 | 92 | 57 | 457 | 224 | 96 | 44 | 364 |
| Total Oncology | 468 | 265 | 140 | 873 | 427 | 291 | 131 | 849 |
| Other | ||||||||
| AmBisome | 4 | 47 | 59 | 110 | 7 | 65 | 56 | 129 |
| Other(5) | 22 | 8 | 21 | 51 | 44 | 8 | 21 | 73 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Gilead Sciences's trodelvy — total revenues?
- Gilead Sciences (GILD) reported trodelvy — total revenues of $457M in Q2 2026.
- How has Gilead Sciences's trodelvy — total revenues changed year-over-year?
- Gilead Sciences's trodelvy — total revenues increased by 25.5% year-over-year, from $364M to $457M.
- What is the long-term trend for Gilead Sciences's trodelvy — total revenues?
- Over 4 years (2021 to 2025), Gilead Sciences's trodelvy — total revenues has grown at a 38.5% compound annual growth rate (CAGR), from $380M to $1.4B.
- What does trodelvy — total revenues mean?
- This metric represents the total gross sales generated from the Trodelvy product line, a key therapeutic asset in the company's oncology portfolio. It reflects the market adoption, pricing power, and clinical demand for this specific antibody-drug conjugate across its approved indications. Monitoring this revenue stream is critical for assessing the company's successful transition into the oncology market and the long-term growth trajectory of its non-virology business units.
Ask your AI about Gilead Sciences's trodelvy — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude